Abstract Number: 0406 • ACR Convergence 2022
Are the BASDAI & BASFI Capturing the Full Impact of Disease Activity on Quality of Life in Women with Axial Spondyloarthritis?
Background/Purpose: The tools to assess disease activity and quality of life in axial spondyloarthritis (axSpA) were developed in ankylosing spondylitis cohorts biased towards inclusion of…Abstract Number: 1032 • ACR Convergence 2022
Anti-arthritogenic Effect of Smoking in Curdlan-Administered SKG Mice
Background/Purpose: Alpha7 nicotinic acetylcholine receptor (α7nAChR), a member of AChR expressed in various immune cells and synoviocytes, has an important role in the anti-inflammatory pathway…Abstract Number: 1601 • ACR Convergence 2022
Female Psoriatic Arthritis Patients Show Differences in Treatment Response to IL12/23 Inhibition in Combination with or Without MTX Compared to Male – Results from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial
Background/Purpose: Subgroup analysis from different clinical trials and real-world data suggest, that there are differences in baseline characteristics, clinical phenotypes, and treatment responses in female…Abstract Number: 0413 • ACR Convergence 2022
Efficacy and Safety of Non-Pharmacological and Non-Biological Therapy: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Background/Purpose: Since the 2016 recommendations for axial spondyloarthritis (axSpA) management, new evidence emerged regarding axSpA treatment. The aim of this work was to update the…Abstract Number: 1033 • ACR Convergence 2022
Risk of Mood Disorders in SpA Patients and Correlations with Disease Activity, Quality of Life and Working Ability: Analysis of a Monocentric Cohort
Background/Purpose: Spondyloarthropathies (SpA) are chronic inflammatory arthritides, characterized by both peripheral and axial skeletal involvement and some typical extra-articular marks; they tend to associate with…Abstract Number: 1612 • ACR Convergence 2022
Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk
Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…Abstract Number: 0416 • ACR Convergence 2022
Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Background/Purpose: Since the 2016 update of the management recommendations for axial spondyloarthritis (axSpA), new evidence has emerged on the efficacy and safety of biological disease-modifying…Abstract Number: 1035 • ACR Convergence 2022
Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies
Background/Purpose: Evidence on the efficacy of advanced therapies for axial involvement in PsA (axPsA) is scarce, largely due to the lack of a widely accepted…Abstract Number: 1768 • ACR Convergence 2022
Sex-Related Differences in Healthcare Utilization in Patients with Inflammatory Arthritis: A Population-based Study
Background/Purpose: Delayed diagnosis of inflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), is associated with joint damage and disability.…Abstract Number: 0796 • ACR Convergence 2022
SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?
Background/Purpose: Spondyloarthritis(SpA) patients are exposed to a variety of immunosuppressors capable of reduce humoral responses to vaccination. In context of the SARS-CoV-2 pandemic, assessment of…Abstract Number: 1037 • ACR Convergence 2022
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies
Background/Purpose: Although the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to assess the activity of axial disease in patients (pts) with PsA, only…Abstract Number: 2108 • ACR Convergence 2022
Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naïve Adults with PsA
Background/Purpose: The IL-23p19 inhibitor guselkumab has shown robust efficacy vs placebo (PBO) in the phase 3 DISCOVER-1 and DISCOVER-2 studies of adults with active PsA,1,2…Abstract Number: 0800 • ACR Convergence 2022
Antibody Response to Shingrix Vaccination in Patients with Rheumatoid Arthritis, Seronegative Spondyloarthropathy and Systemic Lupus Erythematosus on Immunosuppressive Medications
Background/Purpose: In patients with rheumatic diseases herpes zoster (HZ) has been identified as one of the most common infections associated with immunosuppression. Shingrix is a…Abstract Number: 1041 • ACR Convergence 2022
Tofacitinib in Refractory Uveitis – an Observational Study
Background/Purpose: To evaluate the effect of generic tofacitinib in refractory uveitis patients.Methods: It was a prospective observational study of 23 patients of refractory anterior uveitis.…Abstract Number: 2109 • ACR Convergence 2022
Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Background/Purpose: Sustained minimal disease activity (MDA) is only achieved by a small portion of PsA patients (pts). Levels of disease activity consistent with MDA may…
- 1
- 2
- 3
- …
- 6
- Next Page »